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Background: The emergence of resistance to chemotherapy
remains a major problem in the treatment of patients with
small-cell lung cancer. Elevated expression of Bcl-2, a pro-
tein that inhibits programmed cell death or apoptosis, has
been associated with radiation and drug resistance and has
been observed in the majority of small-cell lung cancer speci-
mens and cell lines. Purpose: To test the hypothesis that
Bcl-2 expression levels are critical for inhibiting apoptosis in
small-cell lung cancer cells, we used an antisense strategy to
reduce Bcl-2 expression in these cells in an attempt to restore
the natural occurrence of apoptosis. Methods: Thirteen an-
tisense oligodeoxynucleotides (ODNs) targeting various re-
gions of the bcl-2 messenger RNA and a control scrambled-
sequence ODN were tested to identify the most effective
sequence(s) for reducing Bcl-2 protein levels. Northern and
western blot analyses were used to examine basal bcl-2 mes-
senger RNA and protein levels, respectively, in four human
small-cell lung cancer cell lines (SW2, NCI-H69, NCI-H82,
and NCI-N417). SW2 cells were treated with the antisense
ODNs in the presence of cationic lipids (to facilitate uptake),
and cytotoxic effects were measured by use of a cell viability
assay. Flow cytometric analysis of DNA fragmentation and
cell morphology was also performed. The cytotoxic effect of
the most potent antisense ODN was also tested on the three
other cell lines. Results: The viability of SW2 cells was ef-
fectively reduced by ODNs that targeted the translation ini-
tiation and termination sites of the bcl-2 messenger RNA,
but ODN 2009 that targeted the coding region was the most
cytotoxic. Treatment of SW2 cells with 0.15 µM ODN 2009
for 96 hours reduced their viability by 91% (95% confidence
interval [CI] = 88%-94%) and caused a dose-dependent re-
duction in Bcl-2 levels that became detectable 24 hours after
treatment and persisted up to 96 hours; analysis of cellular
morphology demonstrated that viability was reduced
through apoptosis. Moreover, ODN 2009 at 0.15 µM was
cytotoxic to NCI-H69, NCI-H82, and NCI-N417 cells, result-
ing in decreases in cell viability of 82% (95% CI = 78%-
86%), 100%, and 100%, respectively, after 96 hours of treat-
ment. The cytotoxic effects were inversely correlated with
the basal Bcl-2 levels in the cell lines (r = −.9964). A control
scrambled-sequence oligodeoxynucleotide had no statisti-
cally significant effect on the cell lines (P values ranging from
.38 to .89). Conclusion: We have identified a novel antisense
ODN sequence (ODN 2009) that effectively reduces the vi-
ability of small-cell lung cancer cells by reducing Bcl-2 levels
and facilitating apoptosis. [J Natl Cancer Inst 1997;89:1027-
36]
Lung cancer is the leading cause of cancer deaths in Western
countries, and its incidence continues to rise worldwide (1).
Small-cell lung cancer makes up about 25% of lung cancer cases
and is characterized by a rapid and aggressive clinical course.
After an initial response to chemotherapy, most small-cell lung
cancers relapse in a drug-resistant form, leading to a 2-year
survival of only 5% (1). Despite intensive research, improve-
ments in the treatment of refractory small-cell lung cancer have
remained elusive. Current efforts are directed toward the iden-
tification of novel genetic alterations in small-cell lung cancer
and toward the understanding of mechanisms responsible for
drug resistance. Among the latter, several genetic changes have
been found in small-cell lung cancer that alter drug transport and
activity (2), as well as defects that prevent apoptotic cell death
after cytotoxic damage (3,4).
The bcl-2 proto-oncogene (also known as BCL2) was first
identified as a site involved in a t(14;18) chromosomal translo-
cation in follicular lymphomas (5). The Bcl-2 protein is local-
ized in the endoplasmic reticulum, the outer mitochondrial mem-
brane, and the nuclear envelope (6). Although its mechanism of
action is still unclear, Bcl-2 functions as a suppressor of apop-
totic death triggered by a variety of signals. Recent evidence (7)
suggests that Bcl-2 contributes to cell survival also by dimin-
ishing the rate of cell proliferation. Furthermore, Bcl-2 was
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shown to prevent activation of the ICE protease cascade (8), and
early experiments (9) demonstrated that it cooperates with the
Myc oncoprotein to transform cells. Recently, a link has been
established between expression of bcl-2 in tumors and certain
forms of radiation and drug resistance. For instance, ectopic
expression of bcl-2 in a neuroblastoma cell line that was bcl-2
negative by immunoprecipitation conferred resistance to cisplatin-
and etoposide-induced apoptosis (10), and comparable results
were obtained by use of lymphocytic leukemia cell lines (11). In
small-cell lung cancer, it has been estimated from immunohis-
tochemical and western blot analyses that up to 90% of tumors
(4) and cell lines (12) overexpress bcl-2. However, since the
sensitivity of these assay systems is limited, it remains unclear
whether Bcl-2-negative small-cell lung cancer cells really exist.
The modulatory role of Bcl-2 in the response of small-cell lung
cancers to chemotherapy has been demonstrated by transfection
experiments analogous to those mentioned above: Ectopic ex-
pression of bcl-2 in a small-cell lung cancer cell line increased
the resistance to apoptosis induced by chemotherapy (13). In
view of the prevalence and protective function of Bcl-2, we
hypothesized that Bcl-2 must be critical for inhibiting apoptosis
in small-cell lung cancer cells.
This study was motivated by the lack of appropriate treat-
ments for small-cell lung cancer, as well as the lack of data on
the implication of up-regulated (i.e., increased) bcl-2 expression
in small-cell lung cancer and solid tumors in general. To address
these issues, we have used an antisense strategy to achieve
down-regulation (i.e., a reduction) of bcl-2 expression in small-
cell lung cancer cells. Similar approaches in other tumor models
have resulted in decreased cell survival (14,15), the induction of
apoptotic death (16), and increased drug sensitivity in vitro and
in vivo (11,17). To investigate the issue of sequence dependence
with respect to the effectiveness of antisense treatment, we
tested 13 different antisense oligodeoxynucleotides (ODNs) tar-
geting various regions of the bcl-2 messenger RNA for cytotox-
icity on various small-cell lung cancer cell lines.
Materials and Methods
Cell lines and transfection. We studied the following four human small-cell
lung cancer cell lines: SW2, NCI-N417, NCI-H82, and NCI-H69. All cell lines
were cultured in RPMI-1640 medium (Life Technologies, Ltd. [GIBCO BRL],
Paisley, U.K.) supplemented with 2 mM L-glutamine, 10% fetal calf serum
(FCS), 50 IU/mL penicillin, and 50 mg/mL streptomycin at 37 °C in a humidified
atmosphere with 5% CO2. The SW2 cell line was obtained from the Dana-Farber
Cancer Institute, Boston, MA; the NCI-N417, NCI-H82, and NCI-H69 cell lines
were obtained from the American Type Culture Collection (ATCC), Rockville,
MD. All cells were grown as floating aggregates.
Bcl-2 antisense ODNs. A total of 13 antisense ODNs targeting various re-
gions of the bcl-2 messenger RNA were provided by Novartis Pharma, Basel,
Switzerland. A BLASTN search of a database containing all sequences in the
GenBank, European Molecular Biology Laboratory (EMBL) database, DNA
Data Bank of Japan (DDBJ), and the Protein Data Bank (PDB) revealed no
homology of the ODNs to other human genes except for ODN 2300. All ODNs
were 20-mer (i.e., 20 nucleotides long) phosphorothioates purified by high-
pressure liquid chromatography. The sequences were as follows: 2291, 58-
CGCCATCCTTCCCAGAGGAA-38 ; 2292, 5 8 -CCAGCGTGCGC-
CATCCTTCC-38; 2293, 58-TCCCAGAGGAAAAGCAACGG-38; 2294,
58-TGCAGCTGGCTGGACATCTC-38; 2009, 58-AATCCTCCCCCAG-
TTCACCC-38; 2295, 58-TGTTGACTTCACTTGTGGCT-38; 2011, 58-
GGCAGGCATGTTGACTTCAC-38; 2296, 58-CCTTTTGCATATTT-
GTTTGG-38 ; 2297, 5 8 -TGCTTTAGTGAACCTTTTGC-38 ; 2298,
58-TGTTTCATGGTACATCACTG-38; 2299, 58-TGTTATTTTTTCTTAAA-
CAG-38; 2300, 58-TGTGTGTCTGTCTGTGTGTG-38; and 2017, 58-
GTAAATAGCTGATTCGACGT-38.
The scrambled-sequence controls to ODN 2009 were as follows: sc-12, 58-
TCCCACCTCACCTACATCCG-38; sc-21, 58-ACACCCCAATTCTTCC-
GCCC-38; and sc-48, 58-CTCATTCCTACCGACACCCC-38.
In addition, two 18-mer phosphorothioate ODNs analyzed in a previous study
(18) were used for comparison. One was targeted to the translation initiation site
of the bcl-2 messenger RNA, and the second corresponded to the scrambled-
sequence control. The sequences were as follows: atg, 58-GTGCGCCATCC-
TTCCCAG-38; and sc-31, 58-CGCCAGTCTTGGCTCACC-38. Of all ODNs,
two to three (ODN 2009) different batches were prepared and tested. ODNs were
kept at −20 °C in 10 mM Tris (pH 7.4) and 1 mM ethylenediaminetetraacetic
acid.
Treatment of cells with ODNs. ODNs were delivered to cells in the form of
complexes with the cationic lipid N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate (DOTAP) (Boehringer Mannheim GmbH,
Germany). Equal volumes of ODNs (6 mM) and DOTAP (0.2 mM) in HEPES-
buffered saline were mixed and allowed to form a complex for 10 minutes at
room temperature. The mixture was diluted into 9 volumes of RPMI-1640 cul-
ture medium without FCS and added to cells in culture medium containing 10%
FCS to a final density of 2 × 105 cells/mL. The final concentrations were 0.15
mM ODNs and 5% FCS. Controls were treated with equivalent concentrations of
DOTAP or medium alone. Cells were incubated at 37 °C for different periods of
time, depending on the experiment. For higher ODN concentrations, the molar
ratio of DOTAP to ODN was held constant. In all experiments, different batches
of the ODNs were tested.
Measurement of cytotoxicity. The cytotoxicity of ODNs in small-cell lung
cancer cells was determined by measurement of cell viability by use of a col-
orimetric assay, based on the cleavage of the tetrazolium salt WST-1 (Boeh-
ringer Mannheim GmbH) by mitochondrial dehydrogenases in viable cells (19).
For each treatment, 100 mL of the mixture of cells and ODNs was plated in
triplicates in 96-well plates. ODN concentrations and cell densities were as
described above. Cells were incubated for 96 hours at 37 °C, and then 10 mL of
the WST-1 reagent was added per well and allowed to react for 3 hours at 37 °C.
Absorbance at 450 nm was measured by use of an enzyme-linked immunosor-
bent assay reader (2550 EIA reader; Bio-Rad Laboratories Ltd., Hercules, CA).
Detection of bcl-2 messenger RNA by northern blot analysis. Total RNA
was prepared from 6 × 106 cells by use of the one-step acid guanidinium isothio-
cyanate extraction method (20). For each sample, 10 mg of total RNA was
subjected to electrophoresis on denaturing formaldehyde–agarose gels and trans-
ferred to nylon membranes (Schleicher and Schuell GmbH, Dassel, Germany)
according to standard procedures (21). Membranes were hybridized overnight at
42 °C with an EcoRI restriction fragment composed of nucleotides 1410 to 2340
of the bcl-2 complementary DNA, which had been radiolabeled with 32P by use
of random hexanucleotide primers (Megaprime DNA labeling systems; Amer-
sham International, Little Chalfont, U.K.). Simultaneous hybridization with a
1.3-kilobase (kb) EcoRI/HindIII restriction fragment of the 3.93-kb full-length
chicken b-actin cloned into plasmid pUC9 as described (22) was used as probe
for reference. Blots were exposed to a storage phosphor screen scanned by use
of a phosphorimager (Molecular Dynamics, Sunnyvale, CA). Relative messen-
ger RNA levels were quantified by use of the ImageQuant software (Molecular
Dynamics).
Detection of Bcl-2 protein by western blot analysis. For each treatment, 10
mL of the mixture of cells and ODNs was plated in a 25-cm2 flask and incubated
for 24 hours at 37 °C. ODN concentrations and cell densities were as described
above. Soluble protein extracts were prepared as described previously (23), and
protein concentrations were determined by use of the BCA protein assay reagent
(Pierce Chemical Co., Rockford, IL). One hundred micrograms of soluble pro-
tein per sample was separated on a 12% polyacrylamide–sodium dodecyl sulfate
gel at 50 V for about 16 hours. Electrotransfer to a polyvinylidene fluoride
membrane (Hybond-PVDF; Amersham International) was performed in a semi-
dry blotting chamber (Schleicher and Schuell) at 1 mA/cm2 for 1 hour. The blots
were blocked in Tris-buffered saline containing 5% bovine serum albumin and
5% non-fat milk and then incubated overnight at 4 °C with 200 ng/mL mouse
anti-human Bcl-2 monoclonal antibody (Dako Diagnostics AG, Glostrup, Den-
mark). To detect the primary antibody, we incubated blots with a rabbit anti-
mouse immunoglobulin peroxidase conjugate (Sigma Chemical Co., St. Louis,
MO) for 2 hours at room temperature. The immunocomplex was visualized by
enhanced chemiluminescence by use of the ECL kit (Amersham International),
followed by exposure to x-ray film (Fuji RX). Relative protein levels were
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quantified after the films were scanned with a flat bed scanner (Hewlett Packard
ScanJet IIcx) and the ImageQuant software.
Detection of apoptotic cells based on light scattering and DNA fragmen-
tation. Apoptotic cells were identified by flow cytometric analysis of DNA
fragmentation after the nuclei were stained with propidium iodide in the presence
of ribonuclease A (Boehringer Mannheim) as described previously (24) and by
simultaneous analysis of cell morphology based on light scattering (25). Briefly,
approximately 0.2 × 106 of ODN-treated cells were fixed in 2% paraformalde-
hyde and then made permeable in 0.05% Triton X-100 (Sigma Chemical Co.).
Cells were resuspended in 0.5 mL of 50 mg/mL propidium iodide in phosphate-
buffered saline (PBS) and incubated in the dark for 15 minutes at room tem-
perature. Cells were analyzed by use of a FACSCalibur cytofluorometer (Becton
Dickinson, Mountain View, CA) equipped with a 4-log-decade full-scale am-
plifier gain and an analogue-to-digital converter with 1024 channels.
Determination of viable cell numbers by propidium iodide exclusion and
light-scattering properties. All cells in the culture were harvested and briefly
trypsinized and resuspended in PBS. Immediately before measurement, prop-
idium iodide was added to a final concentration of 10 mg/mL, and the number of
viable cells was measured by flow cytometric analysis during 2 minutes at a
constant flow rate. Based on their morphology, cells were considered intact if
they localized to the lower right quadrant of the contour plot (25). Within this
region, only cells that excluded propidium iodide were considered viable.
Fluorescent microscopy. Untreated SW2 control cells and SW2 cells treated
with 0.45 mM ODN 2009 for 72 hours were trypsinized, fixed in 2% paraform-
aldehyde (Sigma Chemical Co.), and then made permeable in 0.05% Triton
X-100. After being washed with PBS, cells were stained with 5 mg/mL acridine
orange (Sigma Chemical Co.) in PBS and analyzed by use of a Leitz DM RXE
fluorescence microscope (Leica, Wetzlar, Germany).
Statistical analysis. Data represent the means ± 95% confidence intervals
(CIs) of three or four independent determinations. The cytotoxic effect of the
antisense ODNs on SW2 cells and the reduction in Bcl-2 protein levels were
compared with those of the untreated control by use of the Behrens–Fisher-type
t test with unpooled variances. Since multiple comparisons were performed,
Bonferroni’s inequality was implemented for each comparison to control for the
overall type 1 error rate. For example, if the 16 different treatments in the
cytotoxicity screening experiment were compared with the control, statistical
significance for an individual treatment would be determined by a P value of less
than .05/16 (4.0031). Regression analysis was performed to test for correlation
at the .05 significance level between the relative bcl-2 messenger RNA and Bcl-2
protein levels in the cell lines and between the relative levels of Bcl-2 protein and
the sensitivity of the cell lines to antisense treatment. Correlation was considered
significant at P<.05. All P values resulted from the use of two-sided tests.
Results
Basal Levels of Bcl-2 Expression in Small-Cell Lung
Cancer Cell Lines
Up to 90% of small-cell lung cancer tumors and cell lines
have been shown to express the Bcl-2 protein (4,12). To examine
the correlation between bcl-2 transcript and protein expression
in additional small-cell lung cancer cell lines, northern and west-
ern blot analyses were performed. As shown in Fig. 1, A, bcl-2
messenger RNA was expressed in all cell lines, and NCI-H82
and SW2 cells displayed the highest levels (109% and 100%,
respectively). However, Bcl-2 protein levels did not correlate
with messenger RNA expression in the cell lines (correlation
coefficient r 4 −.564; P 4 .436). Bcl-2 could be readily de-
tected in SW2 cells (100%) and in NCI-H69 cells (174%) (Fig.
1, B), whereas faint bands could be seen in NCI-H82 cells (27%)
and NCI-N417 cells (13%) only after overexposure of the film
(Fig. 1, B; lower panel). In the latter cell lines, the levels of Bcl-2
protein were at the detection limit of western blot analysis. SW2
cells were used in subsequent experiments because they ex-
pressed intermediate levels of Bcl-2 protein that were readily
detectable.
Different Cytotoxic Effects on SW2 Cells Shown by
Antisense ODNs Targeting Different Regions of the bcl-2
Messenger RNA
Most studies aimed at reducing Bcl-2 protein levels have used
antisense ODNs targeting the translation initiation site of the
bcl-2 messenger RNA, whereas the 58 end comprising the
7-methylguanosine residue linked to a triphosphate (58 cap) or
the 38 untranslated region proved most effective in down-
regulating the expression of other genes. Since it is not possible
to predict the effectiveness of an antisense ODN solely on the
basis of the two-dimensional structure of the target messenger
RNA, it has been proposed that up to 50 antisense ODNs be
tested to find a potent inhibitor (26). Our previous results (18)
suggested that an antisense 18-mer (ODN atg) directed against
the initiation site (i.e., the region containing the initiation codon
of the translated sequence) of the bcl-2 messenger RNA could
decrease the proliferation of SW2 cells. To assess whether other
antisense ODNs might be more cytotoxic for small-cell lung
cancer cells, we synthesized thirteen 20-mer phosphorothioates
directed against the 58 untranslated region, the translation ini-
tiation site, the coding region, the translation termination site,
and the 38 untranslated region of the bcl-2 messenger RNA.
These ODNs were tested for their effect on SW2 cells by use of
the WST-1 cell viability assay. ODNs were delivered intracel-
lularly with the aid of the cationic lipid DOTAP. Cells were
incubated for 96 hours with 0.15 mM ODN; controls received
medium alone or 5 mM DOTAP.
As shown in Fig. 2, several antisense ODNs affected cell
viability. The 18-mer (ODN atg) caused a statistically significant
Fig. 1. Detection of bcl-2 expression in the following four human small-cell lung
cancer cell lines by northern and western blot analyses: SW2, NCI-H82 (H82),
NCI-N417 (N417), and NCI-H69 (H69). For each cell line, 10 mg of total RNA
was subjected to northern blot analysis and 100 mg of soluble protein was
subjected to western blot analysis, as described in the ‘‘Materials and Methods’’
section. Northern blots were simultaneously hybridized with bcl-2 and b-actin
probes. Cell lines are indicated at the top of the figure. A) Northern blot; B)
western blot. Upper panel: normal exposure. Lower panel: long exposure. Nu-
merical values represent the relative levels of messenger RNA corrected for the
amount of b-actin messenger RNA and of Bcl-2 protein in the cells expressed as
the SW2 cell’s integrated volume, which was quantified after the autoradio-
graphs were scanned as described in the ‘‘Materials and Methods’’ section.
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reduction to 47% (95% CI 4 35%-59%), whereas a scrambled-
sequence control ODN (sc-31) with the same base composition
did not change the activity measured by the WST-1 reagent. The
20-mer ODN 2292 directed against the initiation site was more
cytotoxic than the corresponding 18-mer (ODN atg), and sub-
stantial cytotoxicity was also achieved by two ODNs targeting
the 58 untranslated region (ODN 2293) and the termination site
(ODN 2011), respectively. However, ODN 2009, which targets
codons 141-147 of the bcl-2 messenger RNA, was the most
cytotoxic of all ODNs tested, in that it reduced cell viability to
10% (95% CI 4 5%-15%) relative to that of control-treated
cells. A smaller or no effect was seen for all ODNs directed
against the 38 untranslated region (ODNs 2296-2300 and ODN
2017) and for the ODNs against the coding region (ODN 2294)
and against the termination site (ODN 2295), respectively. This
observation suggests that antisense ODNs directed against re-
gions other than the initiation site might be more effective in-
hibitors of small-cell lung cancer growth.
Rapid and Persistent Reduction in Bcl-2 Protein Levels
Induced by ODN 2009
Nonspecific toxicity of antisense ODNs remains a major
problem. Thus, sequence-specific down-regulation of the target
protein or messenger RNA has to be demonstrated. We therefore
performed western blot analysis to detect Bcl-2 protein levels
after treatment of SW2 cells with antisense ODNs. Northern blot
analysis was not used because of its insufficient sensitivity, since
bcl-2 messenger RNA levels were relatively low (Fig. 1). Only
those ODNs were tested that had an effect on SW2 cell viability.
Cells were incubated for 4, 12, and 24 hours with either 0.15 mM
ODN, 5 mM DOTAP, or medium alone. As determined by quan-
tification of the relative protein levels from the x-ray films, none
of the antisense ODNs reduced Bcl-2 levels at time points earlier
than 24 hours after transfection (data not shown).
As shown in Fig. 3, A, after 24 hours, ODN 2009 caused a
visible reduction in Bcl-2. ODN 2011, which targets the trans-
lation termination site, caused a similar reduction. In contrast, all
other ODNs tested showed little or no reduction in Bcl-2 at that
time point. Since the Bcl-2 protein has a half-life of about 10-12
hours (17), the other ODNs might cause a reduction at later time
points. To test this possibility, we performed western blot analy-
sis after we incubated the cells for 96 hours under the same
conditions. At that time, only ODN 2009 still caused a marked
reduction in Bcl-2 levels (Fig. 3, B). Quantification of the rela-
tive protein levels in Fig. 3 shows that ODN 2009 significantly
reduced Bcl-2 to 18% (95% CI 4 13%-23%) at 24 hours and to
49% (95% CI 4 39%-59%) at 96 hours compared with the
control; a statistically significant reduction to 34% (95% CI 4
26%-42%) was also measured for ODN 2011 at 24 hours. All
other ODNs caused smaller reductions in the level of Bcl-2 at 24
hours, which were statistically significant (P<.02), and showed
no effects at 96 hours. Although we cannot exclude that our
ODNs against the translation initiation site might reduce Bcl-2
protein levels at points between 24 hours and 96 hours, our
results suggest that ODN 2009 causes the strongest and most
persistent reduction in expression of Bcl-2. For this reason, fur-
ther experiments focused on ODN 2009; ODN 2011 was not
studied further because of its lower cytotoxic effect and its short-
lasting down-regulation of bcl-2 expression.
To provide further evidence for the sequence-specific action
of ODN 2009, three different control ODNs were synthesized
with the same base composition but in scrambled order. A
BLASTN search of a database containing all sequences of Gen-
Bank, EMBL, DDBJ, and PDB revealed no homology of the
scrambled-sequence ODNs to human genes (data not shown). To
Fig. 2. Cytotoxic effect of antisense oligode-
oxynucleotides (ODNs) targeting different re-
gions of the bcl-2 messenger RNA on SW2
cells. Cells were treated for 96 hours with me-
dium alone (control), 5 mM of the transfection
reagent N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate (DOTAP),
or 0.15 mM of each ODN. Cell viability was
determined in triplicate cultures by use of the
WST-1 reagent as described in the ‘‘Materials
and Methods’’ section. Values are expressed as
percent of the control’s absorbance at 450 nm.
ODNs were directed against the 58 untranslated
region (ODN 2293), the start site (ODNs atg
[ATG], 2291, and 2292), the coding region
(ODNs 2294 and 2009), the stop codon (ODNs
2295 and 2011), and the 38 untranslated region
(ODNs 2296, 2297, 2298, 2299, 2300, and
2017) of the bcl-2 messenger RNA. ODN sc-31
has the same base composition as ODN atg, but
in scrambled order. Data represent the mean
values ± 95% confidence intervals (n 4 3). Sig-
nificance was determined by a P value <.0031.
The arrangement of the ODNs along their loca-
tion relative to the open reading frame of the
bcl-2 messenger RNA is shown at the bottom.
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test their effect, we incubated SW2 cells for 24 hours with me-
dium alone, DOTAP (5 mM, 10 mM, and 15 mM), or ODNs
(0.15 mM, 0.30 mM, and 0.45 mM). As shown in Fig. 4, the
control ODNs (sc-12, sc-21, and sc-48) did not alter Bcl-2 lev-
els. ODN sc-12 could not be tested at the highest dose because
the stock solution was too diluted. Similarly, DOTAP showed no
effect at either concentration. In contrast, ODN 2009 caused a
dose-dependent reduction in Bcl-2. Quantification of relative
protein levels revealed reductions of 60%, 70%, and 77% for
ODN 2009 at 0.15 mM, 0.30 mM, and 0.45 mM, respectively
(data not shown). Comparable results were obtained when the
same concentrations of ODNs were tested for their effect on the
viability of SW2 cells (data not shown). WST-1 assays were
performed as described above after SW2 cells had been incu-
bated for 96 hours with the different ODNs. ODN 2009 caused
a dose-dependent reduction in cell viability, whereas the
scrambled-sequence controls were not toxic. Taken together,
these results provide strong evidence for the ability of ODN
2009 to reduce Bcl-2 levels and cell viability of SW2 small-cell
lung cancer cells by a sequence-specific mechanism.
Dose-Dependent Apoptosis in SW2 Cells Induced by
ODN 2009
In leukemia cell lines, down-regulation of bcl-2 expression
has been shown to reduce cell viability by induction of apoptosis
(16). To test whether this observation applied also to small-cell
lung cancer cells, flow cytometric analysis was performed to
identify apoptotic cells on the basis of their light-scattering prop-
erties and DNA fragmentation (25). SW2 cells were treated for
72 hours with medium alone, DOTAP (5 mM, 10 mM, and 15
mM), or ODNs (0.15 mM, 0.30 mM, and 0.45 mM). After fixa-
tion and permeabilization, cells were incubated with propidium
iodide and subjected to fluorescence-activated cell sorter analy-
sis.
Fig. 5 shows the results plotted as forward scatter against side
scatter, which allows the identification of morphologically intact
cells, apoptotic cells, and apoptotic bodies. Control-treated cells
localized to the lower right quadrant (Fig. 5, A), and no differ-
ence was observed in the contour plots corresponding to
DOTAP-treated (Fig. 5, B-D) and ODN sc-48-treated (Fig. 5,
E-G) cells, irrespective of the concentrations used. Comparable
results were obtained with ODNs sc-12 and sc-21 (data not
shown). In contrast, a dose-dependent increase in the fraction of
apoptotic cells (upper right quadrant) was induced by ODN 2009
(Fig. 5, H-J). At the highest concentration, only a few morpho-
logically intact cells were detectable. This result indicates that
ODN 2009 reduced SW2 cell viability by the induction of ap-
optosis and that this process was dose dependent.
As shown by fluorescent microscopy in Fig. 6, SW2 cells that
Fig. 3. Western blot analysis of
Bcl-2 protein in SW2 cells after
treatment with antisense oligode-
oxynucleotides (ODNs). Cells
were incubated for 24 hours (A)
or 96 hours (B) with medium
alone (control), 5 mM N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N -
trimethylammonium methylsul-
fate (DOTAP), or 0.15 mM of
each ODN; 100 mg of soluble pro-
tein was analyzed per sample, and
western blotting was performed as
described in the ‘‘Materials and
Methods’’ section. Treatments are
indicated at the top of the figure.
Mean values and 95% confidence
intervals from 3 experiments are
presented.
Fig. 4. Western blot analysis of Bcl-2 protein in SW2 cells
after treatment with various concentrations of oligodeoxy-
nucleotides (ODNs) 2009 and scrambled sequences. Cells
were incubated for 24 hours with medium alone (control),
N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium
methylsulfate (DOTAP) at 5 mM, 10 mM, and 15 mM, or
ODNs at 0.15 mM, 0.30 mM, and 0.45 mM; 100 mg of soluble
protein was analyzed per sample, and western blotting was
performed as described in the ‘‘Materials and Methods’’ sec-
tion. Treatments and concentrations are indicated for each
sample. Samples are distributed among two blots because of
space limitations; control- and DOTAP-treated samples are
included in both blots for reference.
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localized to the upper right quadrant after treatment with ODN
2009 exhibited characteristic morphologic features of apoptosis,
including nuclear fragmentation into clearly visible apoptotic
bodies. This increase in granularity of the cells coincided with
the increase in side light scatter intensity shown in Fig. 5, J. In
contrast, untreated and ODN sc-48-treated SW2 cells that local-
ized to the lower right quadrant (Fig. 5) were morphologically
intact.
Because of incomplete DNA fragmentation, quantification of
apoptotic cells based on the pattern of propidium iodide staining
(data not shown) did not reflect the strong apoptotic effect of
ODN 2009 detected by light-scattering analysis. In the untreated
control, 0.8% of apoptotic cells were measured. Depending on
the concentration, in DOTAP-treated and sc-48-treated cells,
values ranged from 0.8% to 0.9% and from 1.1% to 1.4%, re-
spectively, indicating a minimal effect. Treatment with ODN
2009 increased the mean percentage of cells displaying frag-
mented DNA to 2.3% at 0.15 mM, 5.9% at 0.30 mM, and 8.2%
at 0.45 mM, confirming the dose dependence of this process. A
possible explanation for the difference in apoptotic rates deter-
mined by DNA fragmentation and light-scattering analysis
might be the lack of internucleosomal DNA degradation, which
has been reported for epithelial cells (27). Therefore, to obtain
more accurate values of viability, we examined cells for their
ability to exclude propidium iodide. Quantitation was done by
fluorescence-activated cell sorter analysis after 24, 48, 72, and
96 hours of incubation with two different concentrations of
ODNs. ODN 2292 was included for comparison.
Fig. 5. Morphology of SW2 cells after treatment with oligo-
deoxynucleotides (ODNs) 2009 and the scrambled-sequence
control sc-48. Cells were incubated for 72 hours with medium
alone (control), N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-
trimethylammonium methylsulfate (DOTAP) at 5 mM, 10
mM, and 15 mM, or ODNs at 0.15 mM, 0.30 mM, and 0.45
mM and subjected to flow cytometric analysis. Results are
plotted as forward scatter (FSC) against side scatter (SSC).
Morphologically normal cells are seen in the lower right
quadrant. Treatment and concentrations are listed at the top of
each plot. Apoptotic cells are shown in the upper right corner.
Panel A: control. Panels B-D: DOTAP. Panels E-G: sc-48.
Panels H-J: ODN 2009.
Fig. 6. Fluorescent micrograph of SW2 cells
after staining with acridine orange. A) Un-
treated SW2 cells. B) SW2 cells treated with
0.45 mM oligodeoxynucleotide (ODN) sc-48
for 72 hours. C) SW2 cells treated with 0.45
mM ODN 2009 for 72 hours. Note the nuclear
fragmentation of ODN 2009-treated cells into
apoptotic bodies, which coincides with the in-
crease in side light scatter intensity shown in
Fig. 5, J (original magnification ×1000).
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As shown in Fig. 7, ODN 2009 strongly inhibited cell growth,
which was apparent already after 48 hours. Moreover, at the
highest concentration (0.30 mM), ODN 2009 completely abol-
ished cell proliferation, as shown by the steady decrease in the
number of viable cells (Fig. 7, B). ODN 2292 also inhibited cell
growth, but to a lesser degree than ODN 2009. At 96 hours, the
difference between the effects of these ODNs was highly sig-
nificant (P<.01). Furthermore, ODN 2292 appeared to have only
a transient effect even at high concentrations, since proliferation
rates began to recover after 72 hours. The number of viable cells
was reduced to 28% (95% CI 4 20%-36%) and 5% (95% CI 4
2%-8%) of control values after 96 hours of treatment with 0.15
mM and 0.30 mM ODN 2009, respectively. In agreement with
the results obtained by light-scattering analysis (Fig. 5), our
findings confirm that ODN 2009 causes extensive apoptosis of
SW2 cells.
Cytotoxicity of ODN 2009 on Various Small-Cell Lung
Cancer Cell Lines
The results described so far have demonstrated the potent
cytotoxic effects of ODN 2009 on a single cell line, SW2. There-
fore, using the WST-1 assay, we examined the cytotoxic effect
of ODN 2009 on three other small-cell lung cancer cell lines
(NCI-H82, NCI-H69, and NCI-N417), all of which reveal dif-
ferent basal levels of Bcl-2 protein (Fig. 1). Cells were incubated
for 96 hours with either medium alone, 5 mM DOTAP, or 0.15
mM ODNs.
As shown in Fig. 8, ODN 2009 was cytotoxic to all cell lines
tested, but sensitivities varied among the cell lines. NCI-H69
and SW2 cells were the most resistant, their viability being
reduced to 18% (95% CI 4 14%-22%) and 9% (95% CI 4
6%-12%), respectively, of the untreated control value after treat-
ment with ODN 2009. In contrast, no viable NCI-H82 and NCI-
N417 cells could be detected, and morphologic analysis revealed
no evidence of living cells (data not shown). This result dem-
onstrates that the cytotoxic effect of ODN 2009 was highly
specific and inversely correlated (r 4 −.9964; P 4 .003) with
basal levels of Bcl-2 in small-cell lung cancer cells and that their
survival depends on the protective function of this protein.
Discussion
The emergence of resistance to chemotherapeutic agents re-
mains a major problem in the treatment of patients with small-
cell lung cancer, despite the fact that these patients usually have
a good initial response to chemotherapy. Although a number of
genetic alterations associated with drug resistance in small-cell
lung cancer are known, including the deregulated expression of
proteins involved in drug transport and activity (2), and in cell
cycle checkpoint control (28), few advances have been made in
improving the therapeutic options. The Bcl-2 protein can block
apoptosis by most chemotherapeutic agents (10,11), as has also
been corroborated in small-cell lung cancer cells after ectopic
expression (13). Thus, in view of the prevalence of elevated
Bcl-2 expression in small-cell lung cancer, one might hypoth-
esize that Bcl-2 must be vital for small-cell lung cancer cells. In
our study, we have addressed this issue by using antisense ODNs
to down-regulate bcl-2 expression in small-cell lung cancer cells
and to examine the consequences of disrupted bcl-2 expression
on the viability of small-cell lung cancer cells.
Early studies in cell-free systems suggested that antisense
ODNs be targeted to single-stranded rather than to double-
stranded regions of the RNA for optimal binding and that ODN
length should be kept to a minimum (29). In living cells, how-
ever, finding an antisense ODN with optimal properties has
proved to be a rather empirical task. Hence, antisense ODNs
targeting the 58 end proved most effective for the down-
regulation of expression of c-myc (30), c-Ha-ras (31), and rabbit
globin (32), whereas a 38 untranslated region sequence was a
better target for down-regulation of c-raf expression (33). Anti-
sense ODNs targeting the translation initiation site have been
used for other genes, but screening studies were not always
performed to ensure an optimal effect. So far, sequences in the
coding region have not yet been shown to be useful targets. In
our study, we tested thirteen 20-mer phosphorothioates directed
against the 58 untranslated region, the translation initiation site,
the coding region, the translation termination site, and the 38
untranslated region of the bcl-2 messenger RNA. A gene bank
search revealed no homology of the antisense ODNs to genes
other than bcl-2, except for ODN 2300, which, however, did not
Fig. 7. Determination of viable SW2 cell numbers
by light-scattering analysis and propidium iodide
exclusion. Cells were incubated with medium
alone (control), N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-tr imethylammonium methylsulfate
(DOTAP), or oligodeoxynucleotides (ODNs). Vi-
able cells were quantitated by flow cytometric
analysis on the basis of cell morphology and prop-
idium iodide staining at 24, 48, 72, and 96 hours as
described in the ‘‘Materials and Methods’’ sec-
tion. Data represent mean values (n 4 4). A) 5
mM DOTAP and 0.15 mM ODNs. Mean viable
cell number in untreated control cultures at 96
hours 4 125 × 103 cells/100 mL 4 100%. After
96 hours of treatment with ODN 2009, 36 × 103
cells /100 mL (95% confidence interval [CI] 4 26
× 103-45 × 103 cells/100 mL) remain; this corre-
sponds to 28% (95% CI 4 20%-36%) of the con-
trol mean value. B) 10 mM DOTAP and 0.30 mM ODNs. Mean viable cell number in untreated control cultures at 96 hours 4 127 × 103/100 mL 4 100%. After
96 hours of treatment with 0.3 mM ODN 2009, 6.5 × 103 cells/100 mL (95% CI 4 3 × 103-10 × 103 cells/100 mL) remain; this corresponds to 5% (95% CI 4 2%-8%)
of the control mean value. The 95% CIs for the other data points did not exceed 15% and have been omitted for the sake of clarity.
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reduce bcl-2 expression. The ODNs were first screened for an
effect on small-cell lung cancer cell viability, since preliminary
experiments had shown an 18-mer antisense ODN directed
against the bcl-2 translation initiation site to be cytotoxic to
small-cell lung cancer cells. The results revealed that various
antisense ODNs could reduce SW2 cell viability. ODNs directed
against the translation initiation and termination sites were
roughly equivalent, whereas little or no effect was observed for
all ODNs targeting the 38 untranslated region. It is interesting to
note that an 18-mer targeting the translation initiation site, which
has recently been shown to efficiently potentiate the cytotoxic
effect of doxorubicin on small-cell lung cancer cells (18), was
less cytotoxic than a 20-mer to the same region. This observation
suggests that reducing ODN length might be deleterious to its
effectiveness. An unexpected finding was that an ODN directed
against the coding region of the bcl-2 messenger RNA (ODN
2009) was the most cytotoxic. So far, only ODNs targeting the
translation initiation site or regions immediately downstream
have been shown to down-regulate bcl-2 expression (15,34).
Based on the predicted secondary structure of the bcl-2 messen-
ger RNA, no prominent single-stranded region could be identi-
fied at any of the binding sites of the ODNs that had shown an
effect on cell viability. This result confirms that, with current
tools, it is not possible to predict the effectiveness of an anti-
sense ODN in living cells unless screening experiments are per-
formed.
Establishing that an antisense ODN works through sequence-
specific mechanisms has proved to be not only important but
also difficult. Indeed, many of the early results obtained with the
use of antisense ODNs were later shown to be the consequence
of nonspecific ODN toxicity. Usually, the sequence-specific ef-
fect of an antisense ODN is inferred from the reduction of the
target messenger RNA or protein. In small-cell lung cancer cell
lines, we found bcl-2 messenger RNA levels to be relatively low,
and demonstration of antisense effects was thus based on Bcl-2
protein measurements. Consistent with the results on cell viabil-
ity, ODN 2009 caused the strongest down-regulation of Bcl-2
protein. The effect was dose dependent and lasted up to 96
hours. Antisense ODNs targeting the translation initiation site
were significantly less potent, and their effect was only transient.
A similar observation was described for lymphoma cells, in
which an antisense ODN directed to codons 1 through 6 of the
bcl-2 messenger RNA drastically reduced messenger RNA lev-
els but caused only slow and variable reductions in Bcl-2 protein
levels (17,34). The delayed response was attributed to the long
half-life of Bcl-2 (10-12 hours). This antisense ODN (Anticode
G3139) is currently being investigated in a phase I trial in lym-
phoma patients (35). In contrast to ODNs targeting the transla-
tion initiation site of the bcl-2 messenger RNA, ODN 2009
reduced Bcl-2 protein levels to 19% of the control value within
24 hours, and this effect was reproducible. Three scrambled-
sequence control ODNs with the same base composition did not
alter bcl-2 expression or small-cell lung cancer cell viability,
even when they were tested at higher concentrations. These re-
sults provide strong evidence for a sequence-specific mechanism
of action. It is worth mentioning that, after 96 hours, ODN 2009
still maintained Bcl-2 levels reduced to 50% of the control value,
while all other ODNs failed to show an effect at that time. This
persistent action of ODN 2009 might be desirable for two rea-
sons: 1) It is likely to ensure an optimal and long-lasting anti-
sense effect; 2) the fraction of cells surviving antisense treatment
might be sensitized toward further cytotoxic damage, e.g., by
chemotherapeutic drugs.
It has been shown that DNA fragmentation is not a reliable
hallmark of apoptosis in epithelial cells (27). Similarly, we
failed to accurately separate apoptotic from viable small-cell
lung cancer cells on the basis of their pattern of DNA staining
with propidium iodide. In contrast, as reported by Cotter et al.
(25), apoptotic cells could be readily identified on the basis of
morphologic changes, such as cell shrinkage and increased
granularity, which dramatically changed the forward and side
light scatter properties of the cells. Using flow cytometric analy-
sis of cell morphology and propidium iodide exclusion, we could
demonstrate that ODN 2009 kills small-cell lung cancer cells by
a dose-dependent induction of apoptosis. At 0.30 mM ODN
2009, SW2 cell proliferation was completely inhibited, and the
number of viable cells decreased steadily even after 96 hours.
Furthermore, ODN 2009 proved to be cytotoxic to three addi-
tional small-cell lung cancer cell lines. Surprisingly, we found
comparable levels of bcl-2 messenger RNA in the four small-
Fig. 8. Cytotoxic effect of oligodeoxynucleo-
tide (ODN) 2009 and scrambled-sequence
ODN sc-48 on various small-cell lung cancer
cell lines. Cells were treated for 96 hours with
medium alone (control), 5 mM of the transfec-
tion reagent N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-trimethylammonium methylsulfate
(DOTAP), or 0.15 mM of each ODN. Cell vi-
ability was determined in triplicate cultures by
use of the WST-1 reagent as described in the
‘‘Materials and Methods’’ section. Values are
expressed as percent of the control’s absor-
bance at 450 nm (OD450) and represent the
means ± 95% confidence intervals (n 4 4).
Solid gray bars 4 control; open bars 4
DOTAP; bars with vertical lines 4 ODN sc-
48; solid black bars 4 ODN 2009.
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cell lung cancer cell lines, although Bcl-2 protein levels were
different. Similar observations have been made in normal ger-
minal center B cells (36,37). A recent report (38) suggests that
bcl-2 expression can indeed be negatively regulated through
translational mechanisms by a cis-acting element located up-
stream of the normal coding region of the bcl-2 gene. In general,
Bcl-2 protein levels in the cell lines and their sensitivity to ODN
2009 were inversely correlated, a finding further confirming the
specificity of the effect exerted by this antisense treatment. NCI-
H69 cells were the most resistant, and SW2 cells showed an
intermediate response. In contrast, NCI-H82 and NCI-N417
cells, which revealed barely detectable Bcl-2 levels, were ex-
tremely sensitive.
Despite this clear correlation, however, the cytotoxic effect of
Bcl-2 reduction was disproportional among the cell lines. By the
use of ODN atg, for example, in SW2 cells, reduction of Bcl-2
to 73% of the normal value decreased the viability to 47%. Thus,
SW2 cells could not tolerate reduction of Bcl-2 below a critical
threshold, which was still above the basal levels of Bcl-2 found
in the sensitive cell lines NCI-H82 and NCI-N417. It is unclear
why Bcl-2 appears to be more crucial for the survival of SW2
cells. Our preliminary data suggest that the levels of Bax and
Bak are not dramatically different among the cell lines, and
Bcl-xL levels seem not to be correlated to the cytotoxic effect of
Bcl-2 reduction (data not shown). Since the functional regulation
and the interplay of pro-apoptotic and anti-apoptotic molecules,
such as the interaction of the various Bcl-2 family members, are
only partially understood (39), more information will be neces-
sary to understand the molecular basis of our finding.
In conclusion, our results suggest that Bcl-2 is critical for
inhibiting apoptosis in small-cell lung cancer cells. With ODN
2009, we have identified a novel antisense sequence that most
effectively down-regulates expression of the bcl-2 proto-
oncogene in cells derived from a solid tumor; this sequence
deserves further preclinical and clinical investigation.
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